Article Text

PDF
THU0259 10 Years of Treat-To-Target Therapy in Rheumatoid Arthritis Patients (The Best Study): Clinical and Radiographic Outcomes
  1. I. Markusse1,
  2. L. Dirven1,
  3. M. vd Broek1,
  4. G. Akdemir1,
  5. Y. Goekoop-Ruiterman2,
  6. H. Han3,
  7. P. Kerstens4,
  8. W. Lems5,
  9. T. Huizinga1,
  10. C. Allaart1
  1. 1LUMC, Leiden
  2. 2Haga Hospital, the Hague
  3. 3Maasstad Hospital, Rotterdam
  4. 4Reade
  5. 5VUMC, Amsterdam, Netherlands

Abstract

Background Long term studies with treat-to-target therapy are essential to guide treatment strategies.

Objectives To compare clinical and radiographic outcomes of 4 treatment strategies in early rheumatoid arthritis (RA) patients after 10 years.

Methods The BeSt study enrolled 508 patients with early RA. Patients were randomized to: 1 sequential monotherapy, 2 step-up therapy, 3 initial combination with prednisone, 4 initial combination with infliximab. Treatment adjustments were based on 3-monthly disease activity score (DAS) measurements (DAS>2.4: next step; DAS≤2.4 for ≥6 months: taper to maintenance dose, next if DAS<1.6 for ≥6 months: stop last drug). Functional ability (Health Assessment Questionnaire, HAQ) over time was analyzed with a linear mixed model (LMM). Annual X-rays were scored ine one session by 2 blinded readers with the Sharp van der Heijde Score (SHS). SHS progression was categorized per year into “no” (<0.5), “little” (≥0.5 - ≤5) and “much” (>5) and analyzed over time with a generalized LMM.

Results 10 year follow-up was completed by 313 patients (62%). Drop-out rates were lowest in arm 4. Mean age of completers was 61 years and 67% were female. Mean (SD) DAS was 1.6 (0.8) and mean (SD) HAQ was 0.6 (0.6). 82% had a DAS≤2.4, 53% had a DAS<1.6, 15% were in drug-free remission (DFR) with a mean (median) duration of 52 (58) months. After 10 years, 38% were still on the initial treatment step, others had changed medication at least once. Toxicity was similar in all arms. Table 1 shows outcomes per treatment arm. The initial functional improvement achieved during year 1 was maintained during 10 years. Over time HAQ was significantly lower in arm 4 than in arm 2 (0.52 vs 0.70, p=0.03, other differences non-significant). Ten year progression rates were low in all arms. Over time, patients in arm 3 less often developed progression compared to arm 1 (p=0.03, other comparisons non-significant). If progression was present, estimates were 8, 11, 8 and 5 SHS progression in 10 years in arm 1 to 4, respectively.

Conclusions 10 year follow-up in the BeSt study shows the benefit of continued treat-to-target therapy, steering at low disease activity. After initial improvement functional ability remained stable. Of the completers, 53% and 15% were in DAS- and drug-free remission, respectively. Development of radiographic progression was comparable between groups, although more severe in initial monotherapy arms.

Disclosure of Interest : I. Markusse: None declared, L. Dirven: None declared, M. vd Broek: None declared, G. Akdemir: None declared, Y. Goekoop-Ruiterman: None declared, H. Han: None declared, P. Kerstens: None declared, W. Lems: None declared, T. Huizinga: None declared, C. Allaart Grant/research support: The study was designed by the investigators and supported by a government grant from the Dutch Insurance Companies, with additional funding from Schering-Plough B.V. and Janssen B.V. Data collection, trial management, data analysis and preparation of the manuscript were performed by the authors.

DOI 10.1136/annrheumdis-2014-eular.2015

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.